nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—Ecchymosis—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Duloxetine—Urine output increased—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Duloxetine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Duloxetine—Alopecia—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Duloxetine—Confusional state—Bleomycin—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Duloxetine—Vision blurred—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Duloxetine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Duloxetine—Tremor—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Duloxetine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Duloxetine—Oedema—Bleomycin—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Duloxetine—Erythema—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Duloxetine—Infection—Bleomycin—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Duloxetine—Anaemia—Carmustine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Duloxetine—Back pain—Vincristine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Duloxetine—Vomiting—Teniposide—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Duloxetine—Agitation—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Duloxetine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Duloxetine—Asthenia—Fludarabine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Duloxetine—Rash—Teniposide—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Duloxetine—Dermatitis—Teniposide—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Duloxetine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Duloxetine—Headache—Teniposide—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Duloxetine—Pruritus—Fludarabine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Duloxetine—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Duloxetine—Back pain—Mitoxantrone—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Duloxetine—Leukopenia—Carmustine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Duloxetine—Anorexia—Bleomycin—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Duloxetine—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Duloxetine—Anaemia—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Duloxetine—Agitation—Vincristine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Duloxetine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Duloxetine—Polyuria—Methotrexate—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Duloxetine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Duloxetine—Convulsion—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Duloxetine—Hypertension—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Duloxetine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Duloxetine—Nausea—Teniposide—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Duloxetine—Anaemia—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Duloxetine—Vertigo—Vincristine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Duloxetine—Hepatic failure—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Duloxetine—Leukopenia—Vincristine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Duloxetine—Myalgia—Carmustine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Duloxetine—Chest pain—Carmustine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Duloxetine—Anxiety—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Duloxetine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Duloxetine—Malaise—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Duloxetine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Duloxetine—Convulsion—Vincristine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Duloxetine—Hypertension—Vincristine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Duloxetine—Confusional state—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Duloxetine—Oedema—Carmustine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Duloxetine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Duloxetine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Duloxetine—Myalgia—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Duloxetine—Visual disturbance—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Duloxetine—Cough—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Duloxetine—Infection—Carmustine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Duloxetine—Vomiting—Fludarabine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Duloxetine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Duloxetine—Rash—Fludarabine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Duloxetine—Dermatitis—Fludarabine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Duloxetine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Duloxetine—Pain—Bleomycin—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Duloxetine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Duloxetine—Headache—Fludarabine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Duloxetine—Tachycardia—Carmustine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Duloxetine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Duloxetine—Chest pain—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Duloxetine—Myalgia—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Duloxetine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Duloxetine—Lethargy—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Duloxetine—Discomfort—Mitoxantrone—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Duloxetine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Duloxetine—Oedema—Vincristine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Duloxetine—Anorexia—Carmustine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Duloxetine—Infection—Vincristine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Duloxetine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Duloxetine—Osteoarthritis—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Duloxetine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Duloxetine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Duloxetine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Duloxetine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Duloxetine—Oedema—Mitoxantrone—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Duloxetine—Nausea—Fludarabine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Duloxetine—Infection—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Duloxetine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Duloxetine—Shock—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Duloxetine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Duloxetine—Urticaria—Bleomycin—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Duloxetine—Anorexia—Vincristine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Duloxetine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Duloxetine—Body temperature increased—Bleomycin—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Duloxetine—Insomnia—Carmustine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Duloxetine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Duloxetine—Irritability—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Duloxetine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Duloxetine—Paraesthesia—Carmustine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Duloxetine—Mood swings—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Duloxetine—Somnolence—Carmustine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Duloxetine—Anorexia—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Duloxetine—Ataxia—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Duloxetine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Duloxetine—Decreased appetite—Carmustine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Duloxetine—Insomnia—Vincristine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Duloxetine—Paraesthesia—Vincristine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Duloxetine—Pain—Carmustine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Duloxetine—Constipation—Carmustine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Duloxetine—Breast disorder—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Duloxetine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Duloxetine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Duloxetine—Decreased appetite—Vincristine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Duloxetine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Duloxetine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Duloxetine—Fatigue—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Duloxetine—Asthenia—Bleomycin—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Duloxetine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Duloxetine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Duloxetine—Pain—Vincristine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Duloxetine—Constipation—Vincristine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Duloxetine—Pruritus—Bleomycin—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Duloxetine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Duloxetine—Fatigue—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Duloxetine—Pancreatitis—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Duloxetine—Pain—Mitoxantrone—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Duloxetine—Constipation—Mitoxantrone—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Duloxetine—Abdominal pain—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Duloxetine—Body temperature increased—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Duloxetine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Duloxetine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Duloxetine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Duloxetine—Dysuria—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Duloxetine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Duloxetine—Abdominal pain—Vincristine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Duloxetine—Body temperature increased—Vincristine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Duloxetine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Duloxetine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Duloxetine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Duloxetine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Duloxetine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Duloxetine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Duloxetine—Vomiting—Bleomycin—lymphatic system cancer	0.001	0.001	CcSEcCtD
Duloxetine—Infestation NOS—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Duloxetine—Infestation—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Duloxetine—Rash—Bleomycin—lymphatic system cancer	0.000994	0.000994	CcSEcCtD
Duloxetine—Dermatitis—Bleomycin—lymphatic system cancer	0.000993	0.000993	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000991	0.000991	CcSEcCtD
Duloxetine—Asthenia—Carmustine—lymphatic system cancer	0.000988	0.000988	CcSEcCtD
Duloxetine—Renal failure—Methotrexate—lymphatic system cancer	0.000983	0.000983	CcSEcCtD
Duloxetine—Stomatitis—Methotrexate—lymphatic system cancer	0.000974	0.000974	CcSEcCtD
Duloxetine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000972	0.000972	CcSEcCtD
Duloxetine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000968	0.000968	CcSEcCtD
Duloxetine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000945	0.000945	CcSEcCtD
Duloxetine—Epistaxis—Methotrexate—lymphatic system cancer	0.000943	0.000943	CcSEcCtD
Duloxetine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000943	0.000943	CcSEcCtD
Duloxetine—Asthenia—Vincristine—lymphatic system cancer	0.000943	0.000943	CcSEcCtD
Duloxetine—Diarrhoea—Carmustine—lymphatic system cancer	0.000942	0.000942	CcSEcCtD
Duloxetine—Nausea—Bleomycin—lymphatic system cancer	0.000937	0.000937	CcSEcCtD
Duloxetine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000918	0.000918	CcSEcCtD
Duloxetine—Dizziness—Carmustine—lymphatic system cancer	0.00091	0.00091	CcSEcCtD
Duloxetine—Haemoglobin—Methotrexate—lymphatic system cancer	0.000902	0.000902	CcSEcCtD
Duloxetine—Diarrhoea—Vincristine—lymphatic system cancer	0.000899	0.000899	CcSEcCtD
Duloxetine—Hepatitis—Methotrexate—lymphatic system cancer	0.000897	0.000897	CcSEcCtD
Duloxetine—Haemorrhage—Methotrexate—lymphatic system cancer	0.000897	0.000897	CcSEcCtD
Duloxetine—Pharyngitis—Methotrexate—lymphatic system cancer	0.000891	0.000891	CcSEcCtD
Duloxetine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000886	0.000886	CcSEcCtD
Duloxetine—Urethral disorder—Methotrexate—lymphatic system cancer	0.00088	0.00088	CcSEcCtD
Duloxetine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000876	0.000876	CcSEcCtD
Duloxetine—Vomiting—Carmustine—lymphatic system cancer	0.000875	0.000875	CcSEcCtD
Duloxetine—Dizziness—Vincristine—lymphatic system cancer	0.000869	0.000869	CcSEcCtD
Duloxetine—Rash—Carmustine—lymphatic system cancer	0.000868	0.000868	CcSEcCtD
Duloxetine—Dermatitis—Carmustine—lymphatic system cancer	0.000867	0.000867	CcSEcCtD
Duloxetine—Visual impairment—Methotrexate—lymphatic system cancer	0.000865	0.000865	CcSEcCtD
Duloxetine—Headache—Carmustine—lymphatic system cancer	0.000862	0.000862	CcSEcCtD
Duloxetine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000848	0.000848	CcSEcCtD
Duloxetine—Eye disorder—Methotrexate—lymphatic system cancer	0.000839	0.000839	CcSEcCtD
Duloxetine—Tinnitus—Methotrexate—lymphatic system cancer	0.000837	0.000837	CcSEcCtD
Duloxetine—Vomiting—Vincristine—lymphatic system cancer	0.000835	0.000835	CcSEcCtD
Duloxetine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000833	0.000833	CcSEcCtD
Duloxetine—Rash—Vincristine—lymphatic system cancer	0.000828	0.000828	CcSEcCtD
Duloxetine—Dermatitis—Vincristine—lymphatic system cancer	0.000828	0.000828	CcSEcCtD
Duloxetine—Headache—Vincristine—lymphatic system cancer	0.000823	0.000823	CcSEcCtD
Duloxetine—Nausea—Carmustine—lymphatic system cancer	0.000818	0.000818	CcSEcCtD
Duloxetine—Angiopathy—Methotrexate—lymphatic system cancer	0.000814	0.000814	CcSEcCtD
Duloxetine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000814	0.000814	CcSEcCtD
Duloxetine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000811	0.000811	CcSEcCtD
Duloxetine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000809	0.000809	CcSEcCtD
Duloxetine—Rash—Mitoxantrone—lymphatic system cancer	0.000807	0.000807	CcSEcCtD
Duloxetine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000806	0.000806	CcSEcCtD
Duloxetine—Chills—Methotrexate—lymphatic system cancer	0.000805	0.000805	CcSEcCtD
Duloxetine—Headache—Mitoxantrone—lymphatic system cancer	0.000802	0.000802	CcSEcCtD
Duloxetine—Alopecia—Methotrexate—lymphatic system cancer	0.000793	0.000793	CcSEcCtD
Duloxetine—Mental disorder—Methotrexate—lymphatic system cancer	0.000786	0.000786	CcSEcCtD
Duloxetine—Erythema—Methotrexate—lymphatic system cancer	0.000781	0.000781	CcSEcCtD
Duloxetine—Malnutrition—Methotrexate—lymphatic system cancer	0.000781	0.000781	CcSEcCtD
Duloxetine—Nausea—Vincristine—lymphatic system cancer	0.00078	0.00078	CcSEcCtD
Duloxetine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000765	0.000765	CcSEcCtD
Duloxetine—Nausea—Mitoxantrone—lymphatic system cancer	0.00076	0.00076	CcSEcCtD
Duloxetine—Back pain—Methotrexate—lymphatic system cancer	0.000756	0.000756	CcSEcCtD
Duloxetine—Vision blurred—Methotrexate—lymphatic system cancer	0.000736	0.000736	CcSEcCtD
Duloxetine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000725	0.000725	CcSEcCtD
Duloxetine—Anaemia—Methotrexate—lymphatic system cancer	0.000722	0.000722	CcSEcCtD
Duloxetine—Malaise—Methotrexate—lymphatic system cancer	0.000704	0.000704	CcSEcCtD
Duloxetine—Vertigo—Methotrexate—lymphatic system cancer	0.000702	0.000702	CcSEcCtD
Duloxetine—Leukopenia—Methotrexate—lymphatic system cancer	0.000699	0.000699	CcSEcCtD
Duloxetine—Cough—Methotrexate—lymphatic system cancer	0.000682	0.000682	CcSEcCtD
Duloxetine—Convulsion—Methotrexate—lymphatic system cancer	0.000677	0.000677	CcSEcCtD
Duloxetine—Arthralgia—Methotrexate—lymphatic system cancer	0.000665	0.000665	CcSEcCtD
Duloxetine—Myalgia—Methotrexate—lymphatic system cancer	0.000665	0.000665	CcSEcCtD
Duloxetine—Chest pain—Methotrexate—lymphatic system cancer	0.000665	0.000665	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00066	0.00066	CcSEcCtD
Duloxetine—Discomfort—Methotrexate—lymphatic system cancer	0.000657	0.000657	CcSEcCtD
Duloxetine—Confusional state—Methotrexate—lymphatic system cancer	0.000643	0.000643	CcSEcCtD
Duloxetine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000638	0.000638	CcSEcCtD
Duloxetine—Infection—Methotrexate—lymphatic system cancer	0.000633	0.000633	CcSEcCtD
Duloxetine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000625	0.000625	CcSEcCtD
Duloxetine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000624	0.000624	CcSEcCtD
Duloxetine—Skin disorder—Methotrexate—lymphatic system cancer	0.000619	0.000619	CcSEcCtD
Duloxetine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000616	0.000616	CcSEcCtD
Duloxetine—Anorexia—Methotrexate—lymphatic system cancer	0.000608	0.000608	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000581	0.000581	CcSEcCtD
Duloxetine—Insomnia—Methotrexate—lymphatic system cancer	0.000577	0.000577	CcSEcCtD
Duloxetine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000572	0.000572	CcSEcCtD
Duloxetine—Somnolence—Methotrexate—lymphatic system cancer	0.000567	0.000567	CcSEcCtD
Duloxetine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000561	0.000561	CcSEcCtD
Duloxetine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000554	0.000554	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00055	0.00055	CcSEcCtD
Duloxetine—Fatigue—Methotrexate—lymphatic system cancer	0.00055	0.00055	CcSEcCtD
Duloxetine—Pain—Methotrexate—lymphatic system cancer	0.000545	0.000545	CcSEcCtD
Duloxetine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000525	0.000525	CcSEcCtD
Duloxetine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000521	0.000521	CcSEcCtD
Duloxetine—Urticaria—Methotrexate—lymphatic system cancer	0.000506	0.000506	CcSEcCtD
Duloxetine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000504	0.000504	CcSEcCtD
Duloxetine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000504	0.000504	CcSEcCtD
Duloxetine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00047	0.00047	CcSEcCtD
Duloxetine—Asthenia—Methotrexate—lymphatic system cancer	0.000457	0.000457	CcSEcCtD
Duloxetine—Pruritus—Methotrexate—lymphatic system cancer	0.000451	0.000451	CcSEcCtD
Duloxetine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000436	0.000436	CcSEcCtD
Duloxetine—Dizziness—Methotrexate—lymphatic system cancer	0.000422	0.000422	CcSEcCtD
Duloxetine—Vomiting—Methotrexate—lymphatic system cancer	0.000405	0.000405	CcSEcCtD
Duloxetine—Rash—Methotrexate—lymphatic system cancer	0.000402	0.000402	CcSEcCtD
Duloxetine—Dermatitis—Methotrexate—lymphatic system cancer	0.000402	0.000402	CcSEcCtD
Duloxetine—Headache—Methotrexate—lymphatic system cancer	0.000399	0.000399	CcSEcCtD
Duloxetine—Nausea—Methotrexate—lymphatic system cancer	0.000379	0.000379	CcSEcCtD
